(Q30887420)

27 June 2017

1 reference

https://doi.org/10.1002/14651858.CD002306.pub2

1 reference

29 December 2023

title

Risperidone versus other atypical antipsychotic medication for schizophrenia (English)

1 reference

27 June 2017

0 references

1 reference

S M Gilbody

1

1 reference

27 June 2017

A M Bagnall

series ordinal

2

1 reference

27 June 2017

L Duggan

series ordinal

3

1 reference

27 June 2017

A Tuunainen

series ordinal

4

1 reference

27 June 2017

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

27 June 2017

published in

1 reference

27 June 2017

issue

3

1 reference

27 June 2017

page(s)

CD002306

1 reference

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

A risk-benefit assessment of risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Antipsychotic drugs: clinical pharmacology and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Olanzapine for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Risperidone for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Risperidone: review of its pharmacology and therapeutic use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Myocarditis and cardiomyopathy associated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

The well-being of chronic mental patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Treatment of the neuroleptic-nonresponsive schizophrenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

The effect of risperidone on cognition in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Content and quality of 2000 controlled trials in schizophrenia over 50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Newer atypical antipsychotic medication versus clozapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002306

Clozapine versus typical neuroleptic medication for schizophrenia

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002306

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002306

Treatment-resistant schizophrenia: clinical experience with new antipsychotics

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002306

A rating scale for extrapyramidal side effects

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002306

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002306

Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002306

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002306

Identifiers

DOI

10.1002/14651858.CD002306

1 reference

27 June 2017

1 reference